Fundraising Fox
Proxygen GmbH
36 employees on LinkedIn · 1 known investors
Find your way into Proxygen GmbH
Each arrow is one introduction. Sign up to fill in the first one.
153 people can intro you to Giulio
Ask Jan Steyaert to introduce you to Giulio Superti-Furga
You →Jan · together at European Research Council →Giulio
Sign up to find every way you can get introduced to Proxygen GmbH
- Your email: who you already know at Proxygen GmbH, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Proxygen GmbH team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
Founders & leadership
GS
Giulio Superti-FurgaCo-FounderFounder of Proxygen, which discovers glue degraders — a drug modality targeting protein interactions for therapeutic treatments. He has led biomedical research organizations in both industry and academia and is establishing a research institute focused on metabolism, with expertise spanning systems biology, systems and network medicine, drug discovery, proteomics, and the management of research institutions and companies.
Investors · 1
Frequently asked questions
- What does Proxygen GmbH do?
- Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
- Who founded Proxygen GmbH?
- Proxygen GmbH was founded by Giulio Superti-Furga.
- Who are Proxygen GmbH's investors?
- Proxygen GmbH's investors include Wlanholding.